ONCOCYTE CORP (OCX) Stock News

USA - NASDAQ:OCX - US68235C2061 - Common Stock

3.2 USD

+0.47 (+17.22%)

Last: 6/17/2025, 8:05:27 PM

3.17 USD

-0.03 (-0.94%)

After Hours: 6/17/2025, 8:05:27 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

OCX Latest News, Press Relases and Analysis

All

Press Releases

6 months ago - By: Oncocyte Corporation

Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology

6 months ago - By: Oncocyte Corporation

Oncocyte Reports Q1 2025 Results and Business Progress

6 months ago - By: Benzinga - Mentions: LAND EDIT LINC VTLE ...

Earnings Scheduled For May 12, 2025

6 months ago - By: OncoCyte Corporation

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

6 months ago - By: Zacks Investment Research - Mentions: BYRN MAIA

Best Momentum Stocks to Buy for May 6th

6 months ago - By: Zacks Investment Research - Mentions: BBVA HMY BYRN MAIA

New Strong Buy Stocks for May 6th

6 months ago - By: Oncocyte Corporation

Oncocyte Provides Positive Update on Clinical Trial Progress

7 months ago - By: OncoCyte Corporation

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference

7 months ago - By: Benzinga - Mentions: STRM IBO INNV RSLS ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

8 months ago - By: OncoCyte Corporation

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

8 months ago - By: OncoCyte Corporation

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

9 months ago - By: OncoCyte Corporation

Oncocyte Prices $29.1 Million Equity Offering

9 months ago - By: OncoCyte Corporation

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

10 months ago - By: OncoCyte Corporation

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

10 months ago - By: OncoCyte Corporation

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

a year ago - By: OncoCyte Corporation

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

a year ago - By: BusinessInsider

News Image

OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024

a year ago - By: OncoCyte Corporation

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings

a year ago - By: OncoCyte Corporation

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study

a year ago - By: OncoCyte Corporation

Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms

a year ago - By: OncoCyte Corporation

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

a year ago - By: OncoCyte Corporation

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

a year ago - By: OncoCyte Corporation

Oncocyte Signs Leading Transplant Centers in US and Germany

a year ago - By: InvestorPlace

OCX Stock Earnings: OncoCyte Beats EPS, Misses Revenue for Q2 2024

a year ago - By: OncoCyte Corporation

Oncocyte Announces August Investor Conferences Participation

a year ago - By: OncoCyte Corporation

Oncocyte Appoints Andrea James as Chief Financial Officer

a year ago - By: OncoCyte Corporation

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

a year ago - By: OncoCyte Corporation

Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

a year ago - By: OncoCyte Corporation

Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

a year ago - By: OncoCyte Corporation

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

a year ago - By: OncoCyte Corporation

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine